3D Tissue Models

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2014 University of Florida, Gainesville, FL. Verapamil-SR based and atenolol-based strategies result in similar cardiovascular outcomes in patients with hypertension and prior myocardial infarciton J Am Coll Cardiol (in review)
2. 2014 Proarrhythmic risk of a new atrial-selective repolarization agent AZD7009: A comparison with dofetilide PACE (in review)
3. 2014 Incidence of MI is equivalent with verapamil SR-based and atenolol-based strategies in patients with hypertension and CAD: The International Verapamil SR-TRandolapril study. Hypertension J Am Coll Cardiol (in review)
4. 2014 Mortality is not increased with a verapamil-SR strategy compared with an atenolol strategy in hypertensive patients with CAD: The INternational Verapamil Sr-Trandolapril study. Hypertension (in review)
5. 2014 Low proarrhythmic risk of the new atrial antifibrillatory compound AZD7009: A comparison with dofetilide in canine and rabbit left ventricular wedge preparations PACE (in review)
6. 2014 Dronedarone in patients with implantable cardioverter-defibrillators (ICDs). PACE (in review)
7. 2014 Impact of left ventricular hypertrophy on the prognosis in patients with Type 2 diabetes and nephropathy Insights from the RENAAL study.
8. 2014 Atrial fibrillation Current Treatments in Cardiovascular Medicine. Philadelphia
9. 2014 Slowly activating delayed rectifier K+ current contributes to repolarization in canine left ventricle Cardiovasc Res
10. 2014 Modulation of Late Sodium Current by ATX-II and Ranolazine: Proarrhythmic and Antiarrhythmic Effects Journal of Pharmacology and Experimental Therapeutics
11. 2014 Assessment of the pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans. AM J Cardiol
12. 2014 Minimally Invasive Mitral Valve Surgery: Less may be more In review
13. 2013 Use of Evidence-Based and Secondary Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation AM J Med 2013
14. 2013 Mega-Epsilon Waves on 12-Lead ECG-Just another case of Arrhythmia Right Ventricular Dysplasia/Cardiomyopathy? Journal of Electrocardiology 2103.
15. 2013 Effects of dronedarone started rapidly after amiodarone discontinuation Clin Cardiol 2013 Feb;36(2):88-95
16. 2013 Electrocardiogram Interpretation Chapter 12-Case 93: Andersen-Tawil syndrome. ECG Atlas of Advanced Electrocardiogram Interpretation. Editor: Baranchuk A. Remedia 2003
17. 2013 Predictors of Progression of Recently Diagnosed Atrial Fibrillation in Registry on Cardiac Rhythm DisORDers Assessing the Control of Atrial Fibrillation (RecordAF)-United States Cohort Am J Cardiol 2013;112:79-84
18. 2013 Reversal of Fortunes: Recognizing Misplacement of ECG Electrodes. AM J Med 2013
19. 2013 Use and Associated Risks of Commitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation. Insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry Circulation 2013;128:721-728
20. 2013 Risks and Benefits of Anticoagulation in Atrial Fibrillation. Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry Circ Cardiovasc Qual Outcomes. 2013;06:461-469
21. 2013 Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium Am Heart J 2103;165:477-88
22. 2013 Rate versus rhythm control for management of atrial fibrillation in clinical practice: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry Am Heart J 2013;165:622-9
23. 2013 Cardiovascular Safety In Patients Receiving Roflumilast for the Treatment of Chronic Obstructive Pulmonary Disease Chest 2013 Feb 14.doi:10.1378/chest 12-2332 (Epub ahead of print)
24. 2012 Prevalence of Fragmented QRS and Right Precordial T Wave Inversions in Normal Children Circulation 2012;125(19):P437
25. 2012 Marked Reduction of Cardiac Events by Omega-3 Fatty Acids in Long QT Syndrome Children Carrying KCNQ1 Mutations-A 3-Case Follow-up Report Circulation 2012;125(19):P490
26. 2012 Stroke prevention in atrial fibrillation J Cardiovasc Med (Hagerstown) 2012 Feb;13(2):73-85
27. 2012 Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans Clin Exp Pharmacol Physiol. 2012 Jan;39(1):3-8.
28. 2012 The Food and Drug Administration Decision Not to Approve the 110 Mg Dose of Dabigatran: Give Us a Way Out AM J Med. 2012;125(8)732
29. 2012 Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort : clinical correlates and the effect of rhythm-control therapy Am Heart J. 2102 May;163(5):887-93.
30. 2012 Differentiating electrophysiological effects and cardiac safety of drugs based on the electrocardiogram: A blinded validation Heart Rhythm 2012;9:1706-1715
31. 2012 Selection of Rate versus Rhythm Control for Treatment of Atrial Fibrillation in Clinical Practice: Results from the ORBIT-AF Registry J. Am. Coll. Cardiol. March 2012;59:E623
32. 2012 Gersh, Peter R. Kowey, et al. Comparison of Symptoms and Quality of Life in Atrial Fibrillation: Results from the ORBIT-AF Registry J. Am. Coll. Cardiol. March 2012;59:E621
33. 2012 Simple Prediction of Long-Term Mortality Among Hypertensive Patients With Coronary Artery Disease: New Data From An Extended Follow-Up Of The International Verapamil-SR/Trandolapril Study (INVEST) J. Am. Coll. Cardiol. 2012;59:E1496
34. 2012 Standards for Endpoint Definitions, Terms and Clinical Trial Design Paradigms for Atrial Fibrillation AB35-01 Heart Rhythm. Vol.9, No. 5, May 2012
35. 2012 Modulation of Reverse Use-Dependence by Mexiletine: New Approach to Treat Torsades De Pointes AB43-01 Heart Rhythm. Vol. 9, No. 5, May 2012
36. 2012 Lack of Adaptive Left Ventricular Hypertrophy in Athletes with Arrhythmic Right Ventricular Dysplasia Circulation 2012;125(19):P045
37. 2012 Major Cardiovascular Complications and Mortality in Patients with Takotsubo Cardiomyopathy Circulation 2012;125(19):P478
38. 2011 Atrial Fibrillation: The Role of Geography in the Probability of being Treated by Rhythm-or Rate-Control Strategy Heart Rhythm 2011; 8: S301
39. 2011 Celivarone in patients with an implantable cardioverter-defibrillator: Adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions Heart Rhythm 2011 Oct 4 Epub
40. 2011 Celivarone for Maintenance of Sinus Rhythm and Conversion of Atrial Fibrillation/Flutter J Cardiovasc Electrophysiol 2011 Dec 15. doi: 10.1111/j.1540-8167.2011.02234.x.
41. 2011 Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardiovertor-defibrillator interventions or death: the ALPHEE study Circulation 2011 Dec 13;124(24):2649-60
42. 2011 What’s a Mother to Do? J Cardiovasc Electrophysiol 2011 Oct 10.doi: 10.1111/j 1540-1867.2011.02194.x
43. 2011 Prevalence of J Wave and Early Repolarization Pattern Among Healthy Teenagers and Young Adults ACC 2011, J Am Coll Cardiol
44. 2011 Progression of Atrial Fibrillation in the Recordaf Cohort: Clinical Correlates and the Effect of Rhythm Control Therapy Heart Rhythm 2011; 8: S85
45. 2011 Nonsense-Mediated MRNA Decay Induced by a PKP2 Frameshift Mutation in a Large Family with Arrhythmogenic Right Ventricular Dysplasia Heart Rhythm 2011; 8: S184
46. 2011 Right Bundle Branch Block: The Morphology Differences between Patients with and without Arrhythmogenic Right Ventricular Dysplasia Heart Rhythm 2011; 8: S432
47. 2011 Contribution of Late Sodium Current to Rate Adaption of ventricular repolarization and reverse use-dependence of QT prolonging Agents Heart Rhythm 2011 May; 8(5):762-9. Epub 2010 Dec 22
48. 2011 Electrophysiological properties of HBI-3000: A New Antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocetes J Cardiovasc Pharm 2011;1:79-85
49. 2011 Cardiovascular Safety Profile of Dapoxetine Drugs R D 2011:11(1):1-11
50. 2011 A novel mutation in the KCNH2 gene associated with short QT syndrome. J Mol Cell Cardiol 2011 Mar;50(3):433-41
51. 2011 How much has malpractice litigation altered the care of cardiac rhythm patients? J Cardiovascular Electrophys, 2011: 22;488-89
52. 2011 Atrial fibrillation: pharmacological therapy Curr Probl Cardiol, 2011: Mar;36(3):87-120
53. 2011 Expert Rountable: Managing Atrial Fibrillation (New Antiarrhythmics and New Anticoagulants): Do They Represent Improvements over Previously Available Therapy? The Medical Roundtable Article ID: CV2519
54. 2011 A Piece of My Mind. The Silent Majority JAMA 2011 Jul 6;306(1):18-9
55. 2011 Role of Antiarrhythmic Drugs: Frequent Implantable Cardioverter-Defibrillator Shocks, Risk of Proarrhythmia, and New Drug Therapy Heart Failure Clin 7 (2011) 195-205
56. 2011 Thoroughly measuring the QT interval: can we find the shortcuts? Heart Rhythm 2011 Nov;8(11):1786-7
57. 2011 Real-life observations of clinical outcomes with rhythm-and-rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation) J AM Coll Cardiol 2011 Jul26;58(5):493-501
58. 2011 Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF Am Heart J 2011 Oct;162(4):606-612.e1
59. 2010 A Chinese Cohort of Left Ventricular Noncompaction: Their Clinical and Echocardiographic Characteristics. Circ.2010;122:e745
60. 2010 Efficacy and Safety of Prescription Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation JAMA 2010;304(21):(doi:10.1001/jama 2010.1735)
61. 2010 Can ECG Distinguish Takotsubo Syndrome from Acute Coronary Syndrome? Circ.2010;122:e21
62. 2010 Unique Electrocardiographic Presentations in Patients with Familial Amyloid Neuropathy. Circ. 2010;122:e20
63. 2010 Developing the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a collaborative pan-stakeholder critical path registry model: A Cardiac Safety Research Consortium “Incubator” Think Tank Am Heart J 2010;160:619-26
64. 2010 A Novel Mutation in the KCNH2 Gene Associated with Short QT Syndrome. J Mol Cell Cardiol 2010; Dec 3
65. 2010 Antiarrhythmic Drugs Hurst’s: The Heart. Fuster V, O’Rourke RR, Walsh RA, Poole-Wilson P, eds. 13th Edition. New York: McGraw Hill Medical, Chapter 43, 2010
66. 2010 Takotsubo Syndrome: Does a Markedly Prolonged QT Interval Presage Life-threatening Arrhythmias? Circ.2010;122:e1605
67. 2010 Planning the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a Collaborative Pan-Stakeholder Critical Path Registry Model: a Cardiac Safety Research Consortium “Incubator” Think Tank Am Heart J 2010;159:17-24
68. 2010 Adjuvant therapy for atrial fibrillation Cardiol 2010;6:67-81
69. 2010 Why Did You Order That Echocardiogram? Clin Cardiol 2010;33(10):596--597
70. 2010 Long QT Syndrome Rev Argent Cardiol 2010;78:27-46
71. 2009 Gaps in the ARB Knowledge Base: Are ARBs Effective Ant-Atrial Fibrillation Agents? The Journal of Clinical Hypertension 2009;11:548-551
72. 2009 The pharmacokinetics and hemodynamic effects of PM101, a co-solvent-free intravenous formulation of amiodarone European Journal of Pharmacology 2009;607:167-72
73. 2009 Assessing Proarrhythmic Potential of Drugs When Optimal Studies are Infeasible American Heart Journal 2009;157:827-36
74. 2009 Cellular Basis of the T wave: A Century of Controversy Circulation Arrhythmia Electrophysiol 2009;2:80-88
75. 2009 Assessment of the pharmacokinetic and pharmacodynamic effects of intravenous clopidogrel in humans JACC 2009; 53: A-70
76. 2009 Global Registry on Atrial Fibrillation Management: Regional Differences in Standard of Care JACC 2009; 53: A-115
77. 2009 Differences in patient profiles and management of paroxysmal atrial fibrillation compared to persistent atrial fibrillation in the RecordAF Registry JACC 2009; 53: A-115
78. 2009 Comparison of QTinno, a Fully Automated ECG Analysis program, to Semi- Automated Methods in Analysis of ECGs From a Drug Safety Study JACC 2009; 53; A-375
79. 2009 Comparison of QTinno, a Fully Automated ECG Analysis program, to Semi- Automated Methods in Analysis of ECGs From a Drug Safety Study JACC 2009; 53: A-375
80. 2009 Atrial Fibrillation: Differences in patient characteristics and management between the United States and the rest of the world in the RecordAF registry JACC 2009; 53: A-108
81. 2009 Arrhythmia and the Athlete: Sudden Cardiac Death and Life-Threatening Tachyarrhythmias NA
82. 2009 Predictors of Progression of Recently Diagnaosed Atrial Fibrillation: Results from the RecordAF-US Cohort NA
83. 2009 Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial Circ Arrhythm Electrophysiol.2009;2:652-9
84. 2009 Drug Therapy for Atrial Fibrillation Cardiology Clinics 2009;27:109-23
85. 2009 Bioequivalence of Two Intravenous Amiodarone Formulations in Healthy Subjects The Journal of Clinical Pharmacology 2009;49:407-15
86. 2009 Inhomogeneous Upregulation of Sodium Channel Nav1.5 and It’s Role in Discordant T Wave and Mechanical Alternans in Left Ventricular Hypertrophy Circulation 2009;120:S1469
87. 2009 Predictive Factors for Therapeutic Success in Patients With Recent-onset Paroxsmal and Persistent Atrial Fibrillation in the RecordAf Registry Circulation 2009;120:S702-703
88. 2009 The RecordAF Study: Design, baseline data and profile of patients according to chosen treatment strategy for atrial fibrillation Am J Cardiol. 2009
89. 2009 Dronedarone Circulation 2009;120:636-644
90. 2009 Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: A prospective study Am Heart J 2009;158:163-169.e3
91. 2009 Ventricular transmural repolarization sequence: it’s relationship with ventricular relaxation and role in ventricular diastolic function European Heart Journal 2009;30:372-380
92. 2009 Is there significant transmural gradient in repolarization time in the intact heart? Cellular Basis of the T Wave: A Century of Controversy Cir Arrhythmia Electrophysiol 2009;2:80-88
93. 2009 Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia ablation versus drugs for preventing ICD shocks: role of adjuvant antiarrhythmic drug therapy Circ Arrhythm Electrophysiol. 2009;2:705-11
94. 2009 PM101: A Cyclodextrin-Based Intravenous Formulation of Amiodarone of Adverse Hemodynamic Effects European Journal of Pharmacology 2009;607:167-72
95. 2009 EQ-5D Utility Index in Atrial Fibrillation: Insights from a Large Multinational Registry of Atrial Fibrillation (RecordAF) Circ.2009;120:S395
96. 2009 Upregulation of Cardiac Sodium Channel Nav1.5 and Arrhythmias in Left Atrium in Left Ventricular Hypertrophy Circ.2009;120:S676
97. 2009 Antithrombotic treatment of atrial fibrillation according to risk of thrombosis Eur Heart J 2009: In press
98. 2008 New Horizons in Antiarrhythmic Therapy: Will Novel Agents Overcome Current Deficits? Am J Cardiol 2008; 102 [suppl]:12H-19H
99. 2008 Azimilide Reduces Emergency Department Visits and Hospitalizations in Patients With an Implantable Cardioverter-Defibrillator in a Placebo-Controlled Clinical Trial Journal of the American College of Cardiology 2008;52, No.13
100. 2008 Change In Stroke Volume LV Stimulation Predicts Response To Cardiac Resynchronization Therapy. Heart Rhythm 2008; 5:S382
101. 2008 The Tp-e /QT Ratio as an Arrhythmogenic Index in Patients with Inherited Channelopathies. Heart Rhythm 2008; 5:S296
102. 2008 Facilitation of Drug Induced TdP by Activation of Late INa Heart Rhythm 2008
103. 2008 Contemporary arrhythmia management: Don't say no to drugs NA
104. 2008 Drug Therapy for Atrial Fibrillation Medical Clinics of North America 2008; 92: pp 121-141
105. 2008 Azimilide reduces Emergency Room visits and hospitalizations in patients with an implantable defibrillator in a randomized clinical trial JACC 2008;52:1076-83
106. 2008 Antiarrhythmic Drugs Fuster V, O’Rouke RA, Walsh RA, Poole-Wilson P, et al. Hurst’s The Heart, 12th Edition. New York: McGraw Hill Medical, 2008; 43: pp 1077-1094.
107. 2008 Case Studies with the Experts: Management Decisions in Atrial Fibrillation J Cardiovasc Electrophysiol, Vol. 19, pp. 1-12, Suppl. 1, 2008.
108. 2008 The Geriatric Paradox The American Journal of Geriatric Cardiology 2008; VOL. 17, NO. 2: pp 69-70
109. 2008 Boldly Monitoring Where Few People Have Monitored Before American Journal of Cardiology 2008; 111: 237-238
110. 2008 Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at myocardial infarction: An International Verapamil SR-Trandolapril (INVEST) substudy Am Heart J 2008; 156:241-7
111. 2008 Increased Late INa in Left Atrial Myocytes of Left Ventricular Hypertrophy and Its Role in Genesis of Atrial Early and Delayed Afterdepolarizations Heart Rhythm 2008
112. 2008 Placebo-Controlled Double-Blind Dose –Ranging Study of the Efficacy and Safety of Celivarone for the Prevention of Ventricular Arrhythmia-Triggered ICD Interventions JACC 2008;51(10):A2
113. 2008 Transmural Vs. Apico-basal Dispersion of Repolarization in Genesis of T wave. Heart Rhythm 2008
114. 2008 Donedarone: A New Treatment for Atrial Fibrillation J Cardiovasc Electrophysiol, 2008;19:1220-1226
115. 2007 New horizons in Antiarrhythmic therapy: will novel agents overcome current deficits American Journal Cardiology 2008;102:12H-19H
116. 2007 Placebo-controlled double-blind dose-ranging study of the efficacy and safety of SSR149744C for the prevention of ventricular arrhythmia-triggered ICD interventions JACC (in press) (for ACC ’08)
117. 2007 Efficacy and Safety of Vernakalant Hydrochloride Injection for the Treatment of Atrial Fibrillation After Valvular or Coronary Artery Bypass Surgery AHA Circulation 2007; 116: II-636-7
118. 2007 Reduction in the incidence of atrial fibrillation in high operative risk patients undergoing off pump coronary artery bypass surgery. A promise unkept? Heart Rhythm Journal 2007; 4: 5254
119. 2007 Placebo-controlled double-blind dose-ranging study of the efficacy and safety of SSR149744C in patients with recent atrial fibrillation/flutter Heart Rhythm Journal 2007; 4: 572
120. 2007 The Tp-e/QT ratio serves a universal Arrhythmogenic index in patients with structurally normal hearts Heart Rhythm Society, May 2007
121. 2007 Verapamil-SR strategy is comparable to atenolol strategy at reducing cardiovascular events in patients with prior myocardial infarction: An INVEST substudy. J Am Coll Cardiol 2007;49:232A
122. 2007 Atrial fibrillation in the Post-AFFIRM era US Cardiology 2007;II,113-115.
123. 2007 The diagnosis of cardiac arrhythmias: A prospective multi-center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event monitoring Cardiovasc Electrophysiol 2007;18:1-7.
124. 2007 Cardiovascular risks of anticholinergic therapy: Considerations for office-based management OBG Management 2007: p 7.
125. 2007 Dronedarone for maintenance of sinus rhythm in patients with atrial fibrillation or flutter N Engl J Med 2007;357: pp 987-989.
126. 2007 Does Tpeak-Tend provide an index of transmural dispersion of repolarization? (Letter to the Editor) HRJ 2007; 4: pp 1114-1115.
127. 2007 The QT interval as it relates to the safety of non-cardiac drugs European Heart Journal 2007; 9: G3-G8
128. 2007 Non-Antiarrhythmic Drugs in Atrial Fibrillation: A Review of Non-Arrhythmic Agents in Prevention of Atrial Fibrillation Journal of Cardiovascular Electrophysiology, 2007; Vol.18: pp 1222-1228.
129. 2007 L-type calcium current reactivation contributes to arrhythmogenesis associated with action potential triangulation Cardiovasc Electrophysiol 2007;18:196-203
130. 2007 Pharmacokinetics of antiarrhythmic drugs Fuster V, ed. Hurst’s The Heart. McGraw Hill 2007
131. 2007 Calcium-activated chloride current contributes to action potential alterations in left ventricular hypertrophy rabbit AJP- Heart and Circulatory Physiology 2008;295:H97-H104
132. 2007 Calcium channel recovery Kinetics versus ventricular repolarization… Heart Rhythm 2008;5:271-9
133. 2006 Cardiac implantable electrical devices in the elderly: A promise of prolonged survival and an improved quality of life Am J Geriatr Cardiol 2006;15:75-6.
134. 2006 The meta-analysis: Supportive or illuminating Eur J Cardiol 2006. (editorial)
135. 2006 Detection of malignant cardiac arrhythmias: A prospective multi-center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event monitor. Am Coll Cardiol 2006; II-563
136. 2006 Fast-track training of non-electrophysiologists to implant defibrillators: Is it needed? PACE 2006;29:627-631
137. 2006 Predictors of adverse outcome among patients with hypertension and coronary artery disease J Am Coll Cardiol 2006;47:547-51.
138. 2006 Efficacy of Azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease Am J Cardiol 2006;98:215-218
139. 2006 Critical evaluation of agents for conversion to sinus rhythm in atrial fibrillation EuroPace. 2006;8:651
140. 2006 “Doctor, why didn’t you tell me about this before the ICD?” J Cardiovasc Electrophysiol 2006;17:296-7
141. 2006 Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmia Heart Rhythm 2006;3:948-956
142. 2006 Donedarone: Rhythm and rate control in management of atrial fibrillation. Focus on symptomatic arrhythmia. European Society of Cardiology, August 2006
143. 2006 Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm Am Heart J 2006;151:1043-9.
144. 2006 Sudden death secondary to cardiac arrhythmias: Mechanisms and treatment strategies Curr Opin Cardiol 2006;21:517-525
145. 2005 Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with angiotensin II antagonist Losartan (RENAAL) study Diabetologia 2005;48:1980-7.
146. 2005 New antiarrhythmic pharmacologic therapies and regulatory issues in antiarrhythmic drug development Wang P, ed. New Arrhythmia Technologies. Massachusetts: Blackwell Futura, 2005, pp. 3-13
147. 2005 Does “anti-lipid” also mean “anti-arrhythmic”. J Card Failure 2005;11:691-2. (editorial comment)
148. 2005 Electrocardiography Rosendorff C, ed. Essential Cardiology, 2nd Edition. Orlando: W.B.Saunders 2005.
149. 2005 Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies Am J Cardiol.2005;96:1530-36.
150. 2005 A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous caldaret as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Rationale and design of the Evaluation of Caldaret for Left Ventricular Salvage in Acute MI (EVOLVE) Study J Thromb Thrombolysis 2005;20:147-53
151. 2005 Assessment of the proarrhythmic activity of the novel antiarrhythmic agent AZD7009 and dofetilide in the arterially-perfused canine and rabbit left ventricular wedge preparation and in the anesthetized, methoxamine-sensitized rabbit J Cardiovasc Electrophysiol 2005;16:898-904.
152. 2005 A review of Carvedilol arrhythmia data in clinical trials J CV Pharm & Therapeutics. 2005;10:559-68
153. 2005 Selection of drugs in pursuit of a rhythm control strategy Prog Cardiovasc Dis 2005;48:139-45
154. 2005 Ardial infarction and the future of post myocardial infarction management Clin Cardiol 2005;28:I58-63
155. 2005 Tachycardia Rakel RE, Bope ET, eds. Conn’s Current Therapy. Philadelphia: Elsevier Saunders 2005; pp. 354-360
156. 2005 First experience with a mobile cardiac outpatient telemetry (MCOT) system for the diagnosis and management of cardiac arrhythmia Am J Cardiol 2005;95:878-881
157. 2005 Pharmacologic therapies for atrial fibrillation Am J Geriatr Cardiol 2005;14:62-67
158. 2005 ECG repolarization waves: Their genesis and clinical implications Ann of Noninvasive Electrocardiol 2005;10:211-223.
159. 2005 Losartan and end-organ protection. Lessons from the RENAAL study Clin Cardiol 2005; 28:136-142
160. 2005 Postoperative arrhythmias after cardiac surgery Saksena S, Camm AJ, eds. Electrophysiological Disorders of the Heart. Philadelphia: W.B. Saunders, 2005, pp. 643-652.
161. 2005 Assessment of the proarrhythmic activity of the novel antiarrhythmic agent AZD7009 and dofetilide in the arterially-perfused canine and rabbit left ventricular wedge preparation and in the anesthetized, methoxamine-sensitized rabbit J Cardiovasc Electrophysiol 2005;16:898-904
162. 2005 Making a silk purse out of a sow’s ear. J Am Coll Cardiol 2005;46:688-689
163. 2005 Proarrhythmias and antiarrhythmias: Two sides of the coin Heart Rhythm 2005;2:957-9
164. 2004 Characteristics of contemporary patients with hypertension and coronary artery disease. Clin Cardiol 2004;27:571-576.
165. 2004 EURIDIS and ADONIS Steering Committee and Investigator Circulation 2004;110:III-741
166. 2004 Enhanced transmural dispersion of repolarization is essential to the genesis of the first initiating beat capable of triggering torsades de pointes Heart Rhythm 2004;1:S124
167. 2004 The clinical use of angiotensin converting enzyme (ACE) inhibitors. Prog CV Dis. 2004;47:116-130
168. 2004 You only get so many heartbeats…. J Am Coll Cardiol 2004;43:1209-1210.
169. 2004 Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass graft surgery Am J Cardiol 2004;94:663-665
170. 2004 A case of torsades de pointes in diphenydramine poisoning J Cardiovasc Electrophysiol 2004;15:591-513.
171. 2004 Phase 2 reentry as a trigger to initiate ventricular fibrillation during early acute myocardial ischemia Circulation 2004;110:1036-1041
172. 2004 A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor J Clin Pharmacol 2004;44:21063-1071
173. 2004 Safety and efficacy of intravenously administered tedisamil for rapid conversion of atrial fibrillation or flutter J Am Coll Cardiol 2004;44:99-104
174. 2004 Characteristics of contemporary patients with hypertension and coronary artery disease Clin Cardiol 2004; 27 (10):571-576
175. 2003 Parmley for the INVEST Investigators. Main outcomes from the International VErapamil-Trandolapril Study (INVEST): A randomized trial of a calcium antagonist strategy versus a noncalcium antagonist strategy for treatment of hypertension in patients with coronary artery disease JAMA 2003;290:2805-2816
176. 2003 I’ve fallen and I can’t get up Am J Geriatric Cardiol 2003;12:306. (Commentary)
177. 2003 Overview of the management of AF: What is the current state of the art J Cardiovasc Electrophysiol 2003;14:S275-S280
178. 2003 SB-237376, a new antiarrhythmic compound with dual potassium and calcium channel blocking action J Cardiovasc Pharmacol 2003;41:414-421
179. 2003 Losartan reduces hospitalization for heart failure in patients with diabetes and no prior history of heart failure Circulation 2003;108:IV557
180. 2003 Factors contributing to morbidity and mortality in contemporary CAD patients with hypertension: The international Verapamil/Trandolapril study Circulation 2003;108:IV450
181. 2003 First experience with a mobile cardiac outpatient telemetry system for the diagnosis and management of cardiac arrhythmias PACE 2003;26:1090
182. 2003 Tedisamil for rapid conversion of recent onset atrial fibrillation and flutter to normal sinus rhythm PACE 2003;26:1033
183. 2003 Correction of abnormal repolarization in a rabbit model of acquired LQT2 by increasing slowly activating delayed rectifier K+ current. PACE 2003;26:1043
184. 2003 Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization. Does resynchronization therapy pose a risk for patients predisposed to long QT or torsades de pointes? J Am Coll Cardiol 2003;41:188A.
185. 2003 Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization. Does resynchronization therapy pose a risk for patients predisposed to long QT or torsades de pointes? Circulation 2003;107:740-746.
186. 2003 Supraventricular tachycardia: drugs versus ablation Evidence Based Cardiology. BMJ Books, London, 2003, pp. 567-574
187. 2003 Ventricular repolarization components of the electrocardiogram: Cellular basis and clinical significance J Am Coll Cardiol 2003;42:401-409
188. 2003 Antiarrhythmic drugs for the acute conversion of atrial fibrillation and flutter to sinus rhythm: What we have and what we need Papp JG, Straub M, Ziegler D, eds. Therapeutic Concepts. Jos Press, The Netherlands 2003, pp. 71-79
189. 2003 Ambulatory Electrocardiographic recording Circulation 2003;108:e31-e33
190. 2003 Pharmacologic and nonpharmacologic options to maintain sinus rhythm: Guideline-based and new approaches Am J Cardiol 2003;9133D-38D
191. 2002 Out of phase T wave alternans in left ventricular hypertrophy: Its role in ventricular arrhythmogenesis J Am Coll Cardiol 2002;39:108A
192. 2002 Antiarrhythmic drugs Frishman W, ed. Cardiovascular Pharmacotherapeutics, Second edition. McGraw-Hill, 2002, pp. 225-257
193. 2002 Management of post-operative atrial fibrillation Braunwald, E, ed. Harrison’s Advances in Cardiology. McGraw-Hill, 2002, pp. 410-413
194. 2002 Supraventricular arrhythmias. Crawford M, ed. Current Diagnosis and Treatment in Cardiology. McGraw-Hill, 2002, pp 225-257
195. 2002 Ischemia versus amiodarone induced polymorphic ventricular tachycardia Pace 2002;25:1382-1384
196. 2002 The role of potassium in women’s health. Women’s Health Menopause. Lobo RA, ed. Kluwer Academic Publishers, The Netherlands, 2002, pp. 151-157
197. 2002 Increasing IKs corrects abnormal repolarization in rabbit models of acquired LQT2 and ventricular hypertrophy Am J Physiol 2002;283:H664-H670
198. 2002 Current concepts in the management of long QT syndrome Exp Opin Therap 2002 (Review).
199. 2002 The unnecessary pacemaker controversy revisited PACE 2002;25:269-71
200. 2002 Phase 2 reentry initiates the onset of ventricular fibrillation during early acute myocardial ischemia? Circulation 2002;106:II-128
201. 2002 Pharmacologic management of atrial fibrillation Ganz L, ed. Management of Cardiac Arrhythmia. Humana Press, 2002
202. 2002 Effect of Losartan on cardiovascular outcomes in patients with type 2 diabetes and nephropathy – the reduction of endpoints in NIIDM with the angiotensin II antagonist Losartan (RENAAL) study Circulation 2002;106:II-507
203. 2001 Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachcyardia in acquired long QT syndrome: Direct evidence from intracellular recordings in the intact left ventricular wall Circulation 2001;103:2851-2856
204. 2001 Delayed onset of polymorphic ventricular arrhythmia of increase in QT interval and transmural dispersion of repolarization PACE 2001;24:651
205. 2001 Detecting population-level protective benefits of potassium replacement in diuretic users J Am Coll Cardiol 2001;37:512A
206. 2001 Left ventricular hypertrophy decreases slowly, but not rapidly activating delayed rectifier K+ currents of epicardial and endocardial myocytes in rabbits Biophys J 2001;80:639A
207. 2001 Use of a score system to evaluate proarrhythmic risks of drugs: Comparison between Azimilide and dl-Sotalol PACE 2001;24:S15
208. 2001 Can an increase in transmural dispersion of repolarization facilitate transmural propagation or “reflection” of Phase 2 early afterdepolarization? PACE 2001;24:S17
209. 2001 Bradycardia dependent T wave alternans in left ventricular hypertrophy facilitates the genesis of Phase 2 early afterdepolarization and R-on-T extrasystoles PACE 2001;24:S40
210. 2001 Ventricular hypertrophy amplifies transmural dispersion of repolarization and induces phase 2 afterdepolarization Circulation 2001;104:II-25
211. 2001 Clinical outcomes from the prevention of post-operative arrhythmia II (COPPA II): Evaluation of propafenone Circulation 2001;104:2B
212. 2001 Electrocardiography Rosendorff C, ed. Essential Cardiology. Orlando: W.B.Saunders 2001, pp. 122-142
213. 2001 Left ventricular hypertrophy decreases slowly, but not rapidly activating delayed rectifier K+ currents of epicardial and endocardial myocytes in rabbits Circulation 2001;103:1585-1590
214. 2001 Clinical outcome of patients who develop atrial fibrillation after coronary artery bypass graft surgery PACE 2001;24:191-193
215. 2001 Bioavailability of amiodarone tablets administered with and without food in healthy subjects Am J Cardiol 2001;87:432-435
216. 2001 Restoration of normal ventricular electrophysiology in renovascular hypertensive rabbits after treatment with Losartan J Cardiovasc Pharmacol 2001;37:317-323
217. 2001 INVEST Substudies: Design and Patient Characteristics substudies: Design and patient characteristics Clin Cardiol 2001;24:V9-V11
218. 2001 Ventricular hypertrophy amplifies transmural repolarization dispersion and induces afterdepolarization Am J Physiol 2001;281:H1968-75
219. 2001 Foundations of cardiac arrhythmias: Basic concepts and clinical approaches Circulation 2001;104:e66. (Web site book review)
220. 2001 Analysis of complex arrhythmias Cardiology Special Edition 2001;7:13-17.
221. 2001 The role of potassium The Female Patient 2001, pp 10-13. (Supplement)
222. 2000 Management and prevention of atrial fibrillation after cardiovascular surgery Am J Cardiol 2000;85:20D-24D.
223. 2000 Restoration of normal ventricular electrophysiology in renovascular hypertensive rabbits after treatment with Losartan PACE 2000;23:661
224. 2000 Phase 2 early afterdepolarizations as a trigger to initiate polymorphic ventricular tachycardia in rabbit hypertrophied left ventricle: direct evidence from intracellular recordings. PACE 2000;23:605
225. 2000 Cellular basis for the early repolarization syndrome: a comparison with the Brugada syndrome PACE 2000;23:557
226. 2000 Cellular basis for T wave alternans associated with left ventricular hypertrophy (LVH). PACE 2000;23:661
227. 2000 Classification and pharmacology of antiarrhythmic drugs Am Heart J 2000;140:12-20.
228. 2000 Management of post-operative atrial fibrillation Harrison's On-Line, 2000
229. 2000 Long-term follow up of patients who receive intravenous amiodarone for hemodynamically destabilizing ventricular arrhythmias Am Heart J 2000;139:690-5.
230. 2000 Generic antiarrhythmics - are they therapeutically equivalent for the treatment of tachyarrhythmias?: The experience of practicing electrophysiologists Am J Cardiol 2000;85:1151-53
231. 2000 Electropharmacologic effect of a standard dose of intravenous procainamide in patients with sustained ventricular tachycardia Clin Cardiol 2000;23:171-174
232. 2000 Resuscitation Research and Emergency Waiver of Informed Consent Resuscitation 2000;47:307-310
233. 2000 ST segment elevation and sudden cardiac death: From the Brugada syndrome to acute myocardial ischemia J Cardiovasc Electrophysiol 2000;11:1330-1332.
234. 2000 Effects of captopril treatment of left ventricular hypertrophy on β-adrenergic modulation of L-type Ca2+ current J Pharmacol Exp Therap 2000:292:196-200
235. 2000 Familial hypertrophic cardiomyopathy: Cornering the rat Cardiovasc Res 2000;47:210-211
236. 2000 Therapeutic options for atrial fibrillation: Treatment strategies for the new millenium CVR&R 2000;21:302-319
237. 1999 Atrial arrhythmias after cardiac surgery: Sisyphus revisited? J Am Coll Cardiol 34:348-50
238. 1999 Response to Letter to the Editor "Worried to Death?" Circulation 1999, 1251-1252
239. 1999 Intravenous antiarrhythmic therapy for high risk patients Eur Heart J 1 (Suppl C):C36-C40
240. 1999 The properties of the inward rectifier potassium currents in rabbit coronary arterial smooth muscle cells Eur J Physiol 438:187-194
241. 1999 Efficacy and safety of ibutilide fumurate in patients with atrial flutter or fibrillation following cardiac surgery Circulation 100:369-375
242. 1999 Parenteral antiarrhythmic drugs for supraventricular or ventricular arrhythmias 1st International Congress on Heart Disease, Washington, D.C., May 1999. J Heart Dis 1:14, 1999.
243. 1999 Intravenous antiarrhythmic therapy in the acute control of in-hospital destabilizing ventricular tachycardia and fibrillation Am J Cardiol 84:46R-51R
244. 1999 The relative bioavailability of amiodarone HCL in healthy subjects in a fed and a fasting state 21st Annual Scientific Sessions of the North American Society of Pacing and Electrophysiology, May 1999
245. 1999 A new model for the assessment of the risk of new chemical entities to cause long QT syndrome (LQTS) and torsade de pointes Annual Meeting of General Pharmacology/Safety Pharmacology Meeting, Philadelphia, PA, October, 1999.
246. 1998 Pharmacological effects of antiarrhythmic drugs. Review and Update Arch Intern Med 158:325-332
247. 1998 Conversion efficacy and safety of ibutilide compared with procainamide IV in patients with atrial flutter or fibrillation J Am Coll Cardiol 31:1414
248. 1998 Practical approaches to treating atrial fibrillation Cardiology Review 15:1
249. 1998 Atrial fibrillation trials: Will they teach us what we need to know Am J Cardiol 82:86N-91N
250. 1998 Regression of LV hypertrophy with captopril normalizes membrane current in rabbits Am J Physiol 275 (Heart Circ. Physiol. 44):H1216-H1224
251. 1998 Antiarrhythmic impact of cardiovascular therapies Cardiac Electrophysiology Review 2:123-126
252. 1998 In-hospital management of life-threatening arrhythmias Protocols: Guidelines from Experts in Arrhythmia. Volume 1:3
253. 1998 Left ventricular hypertrophy increase vulnerability to bradycardia and d-sotalol induced early afterdepolarizations J Am Coll Cardiol 31:252A
254. 1998 A broken heart Circulation 98:1349
255. 1998 Acute treatment of atrial fibrillation. Am J Cardiol 81:16C-22C
256. 1997 Ibutilide for post-cardiac surgery AF termination J Am Coll Cardiol 30:4
257. 1997 Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs Am J Cardiol 80 (8A): 16G-23G,
258. 1997 Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. Circulation 96:1330-1336
259. 1997 Top 10 fallacies about nonsustained ventricular tachycardia PACE 20:2825-2847
260. 1997 Intravenous amiodarone. J Am Coll Cardiol 29:1190-1198
261. 1997 Effectiveness of digitalis with or without acebutolol in preventing atrial arrhythmias after coronary artery surgery Am J Cardiol 79:1114-1117
262. 1997 Regression of left ventricular hypertrophy with captopril restores normal ventricular electrophysiology and reduces vulnerability to inducible ventricular fibrillation J Am Coll Cardiol 29:62A
263. 1997 Properties of inward rectifier K+ currents in smooth muscle cells from rabbit coronary arteries Biophys J 72:A251
264. 1997 Clinical value of transtelephonic monitoring in the outpatient management of cardiac arrhythmias Pennsylvania Chapter of the American College of Cardiology, Philadelphia, September 1997
265. 1997 The long-term significance of early conduction disturbances in MI survivors with LV dysfunction PACE 20:1075
266. 1996 Should a moratorium be placed on sublingual nifedipine? JAMA 276:1328
267. 1996 An overview of antiarrhythmic drug management of electrical storm. Can J Cardiol 12(Suppl B):3B-8B
268. 1996 Effect of an intravenous ACE-inhibitor on electrophysiology of normal and hypertrophied feline ventricles Am Heart J 132:989
269. 1996 Atrial fibrillation, anticoagulation and stroke Am J Cardiol 77:38A-44A
270. 1996 Monomorphic right ventricular tachycardia in a patient with mitral valve prolapse PACE 19:509
271. 1996 Atrial fibrillation update 1996 Card Rev and Reports 17: June, July, August, September, 1996.
272. 1996 Restoration of normal ventricular electrophysiology in rabbits after regression of left ventricular hypertrophy with captopril PACE. 19:709
273. 1996 Clinical outcome from the prevention of postoperative arrhythmia (COPPA): A randomized, double-blind, placebo-controlled study of acebutolol and digitalis in patient safety coronary artery bypass graft surgery PACE. 19:608
274. 1996 Overall safety experience with intravenous ibutilide PACE. 19:608
275. 1996 Comparison of intravenous ibutilide versus procainamide for the rapid termination of atrial fibrillation or flutter PACE. 19:608
276. 1996 Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter Am J Cardiol 78 (Supplement 8A):46-52
277. 1996 The effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators J Am Coll Cardiol 28:418-422
278. 1995 Clinical outcome of patients who develop atrial fibrillation after coronary artery bypass graft surgery PACE 18:798
279. 1995 Perspectives on chronic pharmacologic therapy of arrhythmias ACC Current Journal Review 4:26
280. 1995 A new treatment for catastrophic arrhythmias Cardiovasc Rev & Reports, 16:27-29
281. 1995 Drug therapy of ventricular arrhythmia: Principles and practice Drug Therapy of Heart Disease. Franz Messerli (Ed). W. B. Saunders, 1995.
282. 1995 Outcome of patients with nonsustained ventricular tachycardia and severely impaired ventricular function who have negative electrophysiology studies Am Heart J 129:492-496
283. 1995 Supraventricular tachyarrhythmias Crawford M, ed. Current Diagnosis and Treatment in Cardiology. Appleton & Lange 1995, pp. 204-233
284. 1995 Sudden cardiac death: Evaluation and management Kowey PR and Podrid PJ, eds. Cardiac Arrhythmias: Mechanism, Diagnosis and Management. Baltimore: Williams & Wilkins 1995, pp. 974-1003
285. 1995 Ventricular premature beats. Kowey PR and Podrid PJ, eds. Cardiac Arrhythmias: Mechanism, Diagnosis and Management. Baltimore: Williams & Wilkins, 1995, pp. 891-906
286. 1995 Effect of left ventricular hypertrophy and its regression on ventricular electrophysiology and vulnerability to inducible arrhythmia in the feline heart Circulation 91:426-430
287. 1995 Clinically relevant drug interactions Current Opinions in Cardiology 10:26-28
288. 1995 Clinical Competence in Electrocardiography. A Statement for Physicians from the ACP/ACC/AHA Task Force on Clinical Privileges in Cardiology Circulation 91:2683-2686
289. 1995 Clinical Competence in Electrocardiography. A Statement for Physicians from the ACP/ACC/AHA Task Force on Clinical Privileges in Cardiology J Am Coll Cardiol 25:1465-9
290. 1995 A randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with refractory, hemodynamically destabilizing ventricular tachycardia or fibrillation Circulation 92:3255-3263
291. 1995 A dose-ranging study of intravenous amiodarone in patients with malignant ventricular tachycardia Circulation 92:3264-3272
292. 1995 Gender differences in device therapy for malignant ventricular arrhythmias Arch Intern Med 155:2342-2345
293. 1995 Parenteral antiarrhythmics for life threatening ventricular arrhythmia J Cardiovasc Electrophysiol 6:901-913
294. 1995 Clinical predictors of response to intravenous amiodarone in patients with highly malignant ventricular arrhythmias PACE 18:811
295. 1995 Propafenone does not affect defibrillation thresholds in patients with implantable cardioverter defibrillators PACE 18:835
296. 1994 Contemporary management of atrial fibrillation Rhythm 6:1-12
297. 1994 Effects of captopril on ischemic events after myocardial infarction Circulation 90:1731-1738
298. 1994 Management of ventricular arrhythmias after myocardial infarction J Myocard Ischemia 6:27
299. 1994 Overall safety survey for the intravenous amiodarone trials Circulation 90:I-545
300. 1993 Overview of the treatment of myocardial infarction: Acute therapy and prophylaxis Cardiovascular Reviews & Reports 14:54,
301. 1993 The salutary effects of angiotensin converting enzyme inhibition on recurrent myocardial infarction: The SAVE trial experience J Am Coll Cardiol. 21:44A
302. 1993 Outcome of patients with nonsustained ventricular tachycardia and severely impaired left ventricular function who have negative electrophysiology studies Circulation 88:I-605
303. 1993 A multicenter randomized double-blind comparison of intravenous bretylium with amiodarone in patients with frequent malignant ventricular arrhythmia Circulation 88:I-396
304. 1993 The head-up tilt test and cardiovascular neurogenic syncope Am Heart J 125:476
305. 1993 More things that go bang in the night. N Engl J Med 328:1571
306. 1993 Preventing supraventricular arrhythmia after CABG surgery? Choices in Cardiology 7:298
307. 1993 Evidence for a re-excitability gap in man after treatment with a type I antiarrhythmic drug Am Heart J 126:1121
308. 1993 Dose-related hemodynamic effects and pharmacokinetics of oral nicorandil in patients evaluated for chest pain Int J Cardiol 44:203-215
309. 1993 Electrophysiologic testing in patients who respond acutely to intravenous amiodarone for incessant ventricular tachyarrhythmias Am Heart J 125:1628
310. 1993 Polysomnographic and electrocardiographic findings in sudden unexplained nocturnal death syndrome (SUNDS) survivor. Annual Meeting of Association of Professional Sleep Societies (APSS) meeting in Los Angeles, CA, June 1993. Sleep Research, UCLA Brain Research Institute
311. 1992 Effect of gallopamil on electrophysiologic abnormalities and ventricular arrhythmia associated with left ventricular hypertrophy in the feline heart Am Heart J 124:898-905
312. 1992 Considerations for antiarrhythmic drug development in the post-CAST era: Focus on Class III drugs Current Drugs. KCM-B109-B117
313. 1992 In which patients is combination antiarrhythmic therapy appropriate? Choices in Cardiology. 6 Suppl 2: 4-6,
314. 1992 Can post-operative supraventricular tachyarrhythmia be prevented with prophylactic drug therapy? Results of a meta-analysis Am J Cardiol. 69:963-965
315. 1992 Arrhythmias in the elderly. In: Geriatric Cardiology Edited by David T. Lowenthal; F.A. Davis Company, Philadelphia, p 139-157 1992
316. 1992 Does programmed stimulation really help in the evaluation of patients with nonsustained ventricular tachycardia? Results of a meta-analysis Am Heart J 123:481-485
317. 1992 Asymptomatic ventricular ectopic activity and chronic ischemic heart disease Contemporary Management of Ventricular Arrhythmia. Edited by Albert Brest; F.A. Davis, Philadelphia, 1992
318. 1992 Can drug therapy prevent SVT? Choices in Cardiology 5:29
319. 1992 Does prophylactic drug therapy prevent supraventricular arrhythmias after coronary artery surgery? Results of a meta-analysis Clin Res 40:156A
320. 1992 Impact of atrial fibrillation on duration and hospital stay and cost of coronary artery surgery Clin Res 40:365A
321. 1992 Electrophysiologic abnormalities resolve with regression of left ventricular hypertrophy PACE. 15:527
322. 1992 Acute single dose hemodynamics of oral nicorandil in coronary artery disease patients Am Soc Clin Pharmacol Ther
323. 1992 Use-dependent effects of Class I drugs on refractoriness and repolarization PACE 15:552
324. 1992 Things that go bang in the night N Engl J Med 327:1884, 1992 (letter).
325. 1991 Use of propafenone in the treatment of patients with malignant ventricular tachyarrhythmias Can J Cardiol 1991.
326. 1991 What new benefits do Class III drugs offer? Choices in Cardiology 5(1):24
327. 1991 Comparative cost-effectiveness analysis of antiarrhythmic agents Am J Cardiol 68:1662
328. 1991 Current approach to management of arrhythmia: Role of propafenone Cardiovasc Rev Rep 6, 1991
329. 1991 Antifibrillatory effect of class III drug in chronic infarction. Circulation 84:II-505
330. 1991 Cost-effectiveness analysis of antiarrhythmic agents J Am Coll Cardiol 17:56A
331. 1991 Effect of gallopamil on electrophysiologic abnormalities and ventricular arrhythmias associated with left ventricular hypertrophy FASEB J 5:A381
332. 1991 Economic and other factors in the selection of antiarrhythmic drugs New Trends in Arrhythmia 7:344
333. 1991 Comparative antifibrillatory activity of amiodarone versus risotilide in acute ischemia. FASEB J 5:A1216
334. 1991 Cardioprotection: Focus on calcium channel blockers Cardiovasc Rev Rep 12:22,
335. 1991 Does programmed stimulation really have a benefit in treating nonsustained ventricular tachycardia: Meta-analysis. PACE 14:713
336. 1991 A literature-based meta analysis of propafenone for malignant ventricular arrhythmia. Clin Res 1991
337. 1991 Therapy after myocardial infarction: What are the choices? J Cardiovasc Electrophysiol 2(Suppl):5192-5201
338. 1991 Sublingual nifedipine for hypertensive emergencies Lancet 338:881, 1991 (Oct. 5).
339. 1991 Device interaction-antitachycardia pacemakers and defibrillators for sustained ventricular tachycardia PACE 14:302
340. 1991 Electrophysiologic effects of left ventricular hypertrophy: Effect of calcium and potassium channel blockade Circulation 83:2067-2075
341. 1991 What to do about prescribing generic antiarrhythmic drugs Clinical Dialogues on Arrhythmias 5:1
342. 1991 Propafenone for malignant ventricular arrhythmia: An analysis of the literature Am Heart J 121:1178
343. 1990 Device Interaction - Combined use of antitachycardia pacemakers and implantable defibrillators for recurrent sustained ventricular tachycardias PACE 13:496
344. 1990 The cardiac arrhythmia suppression trial: How has it impacted on contemporary arrhythmia management J Cardiovasc Electrophysiol 1:457
345. 1990 Measurement of human ventricular effective refractory periods: Effect of incremental versus decremental extrastimulation J Cardiovasc Electrophysiol 1:506
346. 1990 Clinical guidelines for the use of amiodarone Practical Cardiology 16:47
347. 1990 Clinical management of patients with nonsustained ventricular tachycardia: What do we really know? Cardiology 77:166-180
348. 1990 Clinical and regulatory implications of the Suppression Trial (CAST) Am J Cardiol 65:103-105
349. 1990 Effectiveness of propranolol added to a Type I antiarrhythmic agent for sustained ventricular tachycardia secondary to coronary artery disease Am J Cardiol 65:1328,
350. 1990 Issues in the generic substitution of antiarrhythmic drugs Internal Medicine 11:146
351. 1990 Value of electrophysiologic testing in patients with previous myocardial infarction and nonsustained ventricular tachycardia: Results of a cooperative study Am J Cardiol 65:594
352. 1990 Potassium channels in cardiac arrhythmia: Focus on antiarrhythmic drugs Progress in Clinical and Biological Research 334:111
353. 1990 The effect of potassium-channel blockade on refractoriness and ventricular vulnerability during acute ischemia J Am Coll Cardiol 15:125A
354. 1990 Electrophysiologic effects of left ventricular hypertrophy in vivo: Effect of pharmacologic intervention J Am Coll Cardiol 15:242A
355. 1990 Type A behavior and malignant ventricular arrhythmia J Am Coll Cardiol 15:168A
356. 1990 Effect of oral beta-blockade on isoproterenol tilt test. Clin Res 38:502A
357. 1990 The re-excitability gap: Its importance in the genesis of ventricular arrhythmia in a non-ischemic model of arrhythmia Circulation 82:III-649,
358. 1989 Value of electrophysiologic testing in patients with remote myocardial infarction and nonsustained ventricular tachycardia: Results of a cooperative study Circulation 80:II-662
359. 1989 The effect of thromboxane inhibition on vulnerability to ventricular fibrillation in the acute and chronic feline infarction models Am Heart J 117:848
360. 1989 Interaction between propranolol and propafenone in healthy volunteers J Clin Pharmacol 29:512
361. 1989 Acute electrophysiologic effects and antiarrhythmia/antifibrillatory activity of intravenous amiodarone in a chronic feline infarction model J Cardiovasc Pharmacol 4:389
362. 1989 Electrophysiological effects of left ventricular hypertrophy in the intact cat. Am J Hypertension 2:81
363. 1989 Surgery for expected ventricular tachycardia Am J Cardiol 64:832-833
364. 1989 The effect of beta-adrenergic blockade on vulnerability to ventricular fibrillation and inducibility of ventricular arrhythmia in acute and chronic feline infarction models Am Heart J 118:265
365. 1989 Combination antiarrhythmic therapy with amiodarone Choices in Cardiology 3 (Suppl 3): 21
366. 1989 Masquerading bundle-branch block - Electrophysiological correlation J Electrophysiology 3:156
367. 1989 Differential electrophysiologic activity of recainam in canine atrial and ventricular myocardium: Relationship to plasma and myocardial drug combinations Clin Res 37:843A
368. 1989 Management of reentrant paroxysmal supraventricular tachycardia: Value of medical therapy Clin Res 36:272A
369. 1989 Propranolol for sustained ventricular tachycardia: Results of combination therapy PACE 12:658
370. 1989 Combination antiarrhythmic therapy with amiodarone Clin Res 37:285A
371. 1989 Relative value of rate-slowing versus non-inducibility during electrophysiology-guided therapy of reentrant supraventricular tachycardia PACE 12:684
372. 1988 The Cardiovascular and Renal Drugs Advisory Committee's view of the TPA controversy and the drug approval process JAMA 260:2250
373. 1988 The calamity of cardioversion of the conscious patient Am J Cardiol 61:1106
374. 1988 Effect of antiarrhythmic drugs on defibrillation threshold: Case report of an adverse effect of mexiletine and review of the literature PACE 11:7
375. 1988 Products of arachidonic acid metabolism and vulnerability to ventricular fibrillation during ischemia in the cat Am Heart J 116:1194
376. 1988 Diagnosis and treatment of cardiac rhythm disorders in the elderly Clinics in Geriatric Medicine, January, 1988
377. 1988 Safety and efficacy of amiodarone: The low-dose perspective Chest 93:54
378. 1988 Adverse reactions to antiarrhythmic drugs: Prevalence and prevention Rhythmology 2:9,
379. 1988 Long-term follow-up of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs selected by electrophysiologic testing Clin Res 36:296A
380. 1988 Long-term survival of patients with ventricular tachyarrhythmias treated with an automatic implantable cardioverter-defibrillator Clin Res 36:790A
381. 1988 Electrocardiographic and electrophysiologic effects of oral recainam. Clin Res. 36:361A
382. 1988 Oral recainam for inducible sustained ventricular tachycardia Clin Res 36:327A
383. 1988 Implementation of an electrode-catheter resterilization program: Feasibility and safety Clin Res 36: A
384. 1988 Induction of ventricular tachyarrhythmias during implantation of the automatic cardioverter/defibrillator Clin Res 36:276A
385. 1988 Electrocardiographic effects of nortriptyline in the very elderly depressed Clin Res 36:296A
386. 1988 Benefit-risk assessment in clinical research J Am Coll Cardiol 12:577
387. 1988 A clinician's approach to diagnosing supraventricular tachycardia J Crit Illness 3:39
388. 1988 Electrophysiologic testing in nonsustained ventricular tachycardia Cardiology Board Review 5:37
389. 1988 Role of permanent pacemakers in the pharmacologic therapy of patients with reentrant tachyarrhythmias PACE 11:83
390. 1988 Supraventricular tachycardia in an adolescent female with syncope Rhythmology 2:17
391. 1987 Drug interactions with propafenone J Electrophysiol 1:568
392. 1987 Determinants of reperfusion ventricular fibrillation in the cat Clin Res 35:298A
393. 1987 Acute on chronic coronary occlusion: Effect of reperfusion Clin Res 35:279A
394. 1987 Effect of procainamide on ventricular refractoriness and pacing threshold: Absence of use-dependency Fed Proc 46:871
395. 1987 Nitrous oxide anesthesia in patients with ischemic chest discomfort: Effect on beta-endorphins Clin Res 35:293A
396. 1987 Propranolol for sustained ventricular tachycardia: Results of combination therapy. Clin Res 35:298A
397. 1987 Electrophysiologic profile of recainam, a new antiarrhythmic agent, determined by intracardiac electrophysiologic measurements in man PACE 10:993
398. 1987 Propafenone for the treatment of malignant ventricular arrhythmias Circulation 76 (Suppl IV):IV-521
399. 1987 The FDA Cardio-Renal Committee replies (rt-PA issue). The Wall Street Journal, August 12, 1987.
400. 1987 Nitrous oxide analgesia for ischemic chest discomfort: Effect on beta-endorphins J Clin Pharmacol 27:957
401. 1987 Electrophysiology of beta-blockers in supraventricular arrhythmia Am J Cardiol 60:32-38D
402. 1987 The case for explanation of the automatic implantable cardioverter-defibrillator Am J Cardiol 59:1210
403. 1987 Electrophysiologic effects, clinical efficacy and safety of intravenous and oral Nadolol in refractory supraventricular tachyarrhythmias: A ulticenter study Am J Cardiol 59:307
404. 1987 Effect of calcium-binding additives on ventricular fibrillation and repolarization changes during coronary angiography J Am Coll Cardiol 10:1249
405. 1987 Electrophysiology testing in patients with nonsustained ventricular tachycardia Am J Cardiol 59:841
406. 1987 Ventricular fibrillation during coronary arteriography: The precatheterization QT interval J Electrocardiography 20:255
407. 1986 Safety and efficacy of amiodarone: The low-dose perspective Chest 89:477S
408. 1986 Effect of thromboxane inhibition on vulnerability to ventricular arrhythmia in acute and chronic feline infarction models J Clin Pharmacol 26:554
409. 1986 Anti-fibrillatory effect of acute amiodarone administration: An effect independent of Class III antiarrhythmic activity? J Am Coll Cardiol 7:81A
410. 1986 Effect of a thromboxane synthetase inhibitor, CGS-13080, on vulnerability to ventricular fibrillation Am Heart J 111:683
411. 1986 Prayer-meeting cardioversion (letter). Ann Intern Med 104:727-728
412. 1986 Drug therapy of ventricular fibrillation American Heart Association, ECC Subcommittee Newsletter 9:5
413. 1986 Pacemaker therapy: A comprehensive review Cardiology Product News 6, No.2, 40-51,
414. 1986 Clinical applications of electrophysiology to coronary heart disease. Guiding treatment Atherosclerosis Reviews 14:91
415. 1986 Pacing-induced angina and inducibility of ventricular arrhythmias Am J Cardiol 58:90
416. 1986 Uses and limitations of electrophysiology studies for the selection of antiarrhythmic agents PACE 9:231
417. 1986 Arachidonic acid metabolites and vulnerability to ventricular fibrillation in the cat Clin Res 34:29lA
418. 1986 Electrophysiologic effects of PGEl in man Circ Res 34:866A
419. 1986 Direct recording of monophasic action potentials in patients with catecholamine-sensitive ventricular arrhythmia Clin Res 34:856A
420. 1985 Electrophysiologic studies of the ventricle Cardiovasc Clinics 16:83
421. 1985 Surgical management and mapping of cardiac arrhythmias Cardiovasc Clinics 16:151
422. 1985 Clinical pharmacology of antiarrhythmic agents Cardiovasc Clinics 16:287
423. 1985 Pacemakers: 1985 Surg Clin North Am 65:595
424. 1985 Temporary cardiac pacing in the emergency unit Current Topics in Emergency Medicine, Vol 1 (#4),
425. 1985 Arrhythmia inducibility and ventricular vulnerability in a chronic feline infarction model Am Heart J 110:955
426. 1985 The mechanism of the anti-fibrillatory effects of Class III drugs. Experience with bretylium and clofilium Am Heart J 110:363
427. 1985 Effect of leukotriene receptor blockade on vulnerability to ventricular fibrillation in the cat Clin Res 33:178A
428. 1985 Emergency room evaluation of patients with chest pain syndromes Current Topics in Emergency Medicine, Vol 1 #1
429. 1985 Tocainide .... the new kid on the block Cardiovasc Med 10:10
430. 1985 The effect of site of overdrive on dispersion on ventricular refractoriness Am J Cardiol 55:1339
431. 1985 Bethanidine sulfate: Efficacy in prevention of ventricular tachyarrhythmias during programmed stimulation. Report of a multicenter study of 56 patients J Am Coll Cardiol 6:510
432. 1985 Emergency decisions in managing supraventricular tachycardia Cardiology Emergency Decisions I (Vol 6):1,
433. 1985 Ventricular fibrillation during coronary arteriography: The precatheterization QT interval Clin Res 33:166A
434. 1985 New onset of reentrant ventricular tachycardia after incidental aneurysmectomy Clin Res 33:740A
435. 1985 Non-sustained ventricular fibrillation is an index of vulnerability changes in the acute feline infarction model Clin Res 33:207A
436. 1985 Determination of ventricular effective refractory periods. Does hysteresis exist? PACE 8:305
437. 1985 Value of electrophysiologic testing in patients with nonsustained ventricular tachycardia Clin Res 33:251A
438. 1985 Intravenous nadalol for refractory supraventricular tachycardia: Mechanisms, electropharmacology, efficacy and safety PACE 8:305
439. 1985 Effect of calcium-binding additives on ventricular fibrillation and repolarization changes during coronary angiography Circulation 72: Suppl II1-401
440. 1985 The effect of beta adrenergic blockade on inducibility of ventricular arrhythmia in a chronic feline infarction model Chest 88:255
441. 1985 Effect of calcium channel blockade on intra-atrial reentry tachycardia Clin Res 33:749A
442. 1985 Effect of BW755C on vulnerability to ventricular fibrillation in the cat The Pharmacologist 27:214
443. 1984 The mechanism of the anti-fibrillatory effects of Class III drugs. Experience with bretylium and clofilium Circulation 70:Suppl II-92
444. 1984 Bethanidine Sulfate: Efficacy in prevention of ventricular tachyarrhythmias during programmed stimulation Circulation 70:Suppl II-56
445. 1984 The effect of left ventricular hypertrophy on inducible ventricular arrhythmias Circulation 70:Suppl II-224
446. 1984 The effect of site of overdrive on dispersion of ventricular refractoriness Clin Res 32:671A
447. 1984 Effect of a thromboxane inhibitor on ventricular vulnerability during acute myocardial infarction in the cat Circulation 70:Suppl II-97
448. 1984 Effect of myocardial ischemia on inducibility of ventricular arrhythmia by extrastimulation Circulation 70:Suppl II-401
449. 1984 Arrhythmia inducibility and ventricular vulnerability in a chronic feline infarction model Chest 86:325
450. 1984 Influence of site of stimulation on measurement of ventricular vulnerability during acute ischemia in the cat Clin Res 32:166A
451. 1984 Effect of beta-adrenergic blockade on vulnerability to ventricular fibrillation in the cat Clin Res 32:166A
452. 1984 Electrophysiologic testing for sustained arrhythmias in patients with hypertrophic obstructive cardiomyopathy Clin Res 32:181A
453. 1984 Emergency room management of patients with ischemic heart disease Current Topics in Emergency Medicine Vol 1:#2,
454. 1984 Influence of site of stimulation on measurements of ventricular vulnerability in the normal and ischemic feline heart. Am J Cardiol 54:421
455. 1984 Vulnerability to ventricular fibrillation in patients with clinically manifest ventricular tachycardia Am Heart J 108:884
456. 1984 The significance of ventricular fibrillation associated with acute myocardial infarction: A reappraisal Cardiovasc Rev Rep 5:552
457. 1984 Prospective medicare reimbursement: Legal ramifications for physicians The Jurist (Temple University School of Law) 6:40
458. 1984 Electrophysiologic testing for sustained arrhythmias in patients with hypertrophic obstructive cardiomyopathy N Engl J Med 310:1566
459. 1984 Late induction of ventricular tachycardia in patients with ventricular fibrillation associated with acute myocardial infarction. J Am Coll Cardiol 3:690
460. 1984 ST segmental elevation with ventricular aneurysm: Results of encircling endocardial ventriculotomy J Electrocardiography 17:75,
461. 1983 Programmed electrical stimulation of the heart in patients with coronary artery disease Am J Cardiol 41:531
462. 1983 Pacemaker overutilization: Another perspective PACE 6:982
463. 1983 The relationship of changes in refractoriness and vulnerability to ventricular fibrillation during acute myocardial infarction Effect of bretylium tosylate. Clin Res 31:661A
464. 1983 Influence of dispersion of refractoriness on vulnerability to ventricular fibrillation during acute myocardial ischemia Clin Res 31:177A
465. 1983 The repetitive extrasystole as an index of vulnerability to ventricular fibrillation during myocardial ischemia in the canine heart Am Heart J 106:1321
466. 1983 Decreased vulnerability to ventricular fibrillation by vasodilator-induced baroreceptor sensitization Cardiovasc Res 17:106
467. 1983 Influence of intracoronary platelet aggregation on ventricular electrical properties during partial coronary stenosis Am J Cardiol 51:596
468. 1983 Vulnerability to ventricular fibrillation in patients with clinically manifest ventricular tachycardia J Am Coll Cardiol 1:622
469. 1983 Measurements of ventricular vulnerability in the normal and ischemic feline ventricle Clin Res 31:661A
470. 1983 Use of multiple drive cycle lengths for arrhythmia induction in patients with sustained arrhythmia Clin Res 31:661A
471. 1983 Effect of chronic use of digitalis on the inducibility of ventricular arrhythmia in patients with coronary heart disease Clin Res 31:185A
472. 1983 Effects of alpha-adrenergic stimulation on ventricular electrical properties in normal canine heart Am Heart J 105:366
473. 1983 Overdrive pacing for ventricular tachyarrhythmias. A reassessment Ann Intern Med 99:651
474. 1983 The effect of procainamide on dispersion of ventricular refractoriness Am J Cardiol 52:279
475. 1983 Pacemaker overutilization: A critique of the Scherlis report Am J Cardiol 51:1042
476. 1982 Effects of prostacyclin (PGI2) on vulnerability to ventricular fibrillation in the normal and ischemic canine heart Eur J Pharmacol 80:83
477. 1982 The effect of heart failure on induced ventricular arrhythmia. Clin Pharmacol Ther 31:269
478. 1982 Yield of ventricular arrhythmias by extrastimulation compared with ambulatory monitoring in patients with coronary heart disease Clin Res 30:669A
479. 1982 The effect of procainamide on dispersion of ventricular refractoriness Clin Res 30:678
480. 1982 Is beta blockade adequate in patients referred for coronary surgery? Clin Res 30:667A
481. 1982 Late induction of ventricular tachycardia in patients with ventricular fibrillation associated with acute myocardial infarction Circulation 66: Suppl I1-145
482. 1982 Incidence of inducible ventricular arrhythmias in patients with coronary artery disease Circulation 66 II-146
483. 1982 The QT interval and dispersion of ventricular refractoriness Clin Res 30:669A
484. 1982 Atrial Ta segment, tachyarrhythmias and atrial coronary disease Clin Res 30:677A
485. 1982 Use of radionuclide ventriculography for assessment of changes in myocardial performance induced by disopyramide phosphate. Am Heart J 104:769
486. 1982 Disopyramide Phosphate: Clinical Assessment and application J Cardiovasc Med 6:997
487. 1981 The repetitive extrasystole as an index of vulnerability to ventricular fibrillation during myocardial ischemia Am J Cardiol 47:391
488. 1981 The effects of nitroglycerin on intracoronary platelet aggregation and ventricular vulnerability during partial coronary stenosis Am J Cardiol 47:489
489. 1981 Nitroglycerin induced baroreceptor sensitization and protection against vulnerability to ventricular fibrillation Circulation 64: Suppl IV-71
490. 1981 The repetitive extrasystole threshold as an index of vulnerability to ventricular fibrillation in patients with coronary disease Clin Res 29:654A
491. 1981 Multiple ventricular responses in patients with stable coronary disease Clin Res 29:215A
492. 1980 Use of radionuclide ventriculography for assessment of changes in myocardial performance induced by disopyramide phosphate Circulation 62: Suppl 11-231
493. 1980 Effects of prostacyclin and prostaglandin El on vulnerability to ventricular fibrillation in the normal heart Clin Res 28:188A
494. 1980 Role of brief electrocardiographic screening for exposure of serious ventricular arrhythmia among patients with coronary heart disease Practical Cardiology 6:96
495. 1980 The effects of prostacyclin on vulnerability to ventricular fibrillation during acute myocardial ischemia Clin Res 28:188A
496. 1980 Coronary Arteriography for Whom? Am J Cardiol 45:527
497. 1980 The repetitive extrasystole as an index of vulnerability to ventricular fibrillation Clin Res 28:615A
498. 1980 Effect of alpha-adrenergic receptor stimulation on ventricular electrical properties in the normal canine heart The Physiologist 23:160
499. 1980 Role of platelet activation in exercise-induced malignant ventricular arrhythmia Circulation 62: Suppl II-276
500. 1979 Atrial fibrillation as a rhythm of choice Circulation 59-60, Suppl II-253
501. 1979 Pacemaker removal after unnecessary implantation: clinical experience and analysis of cost Clin Res 27:565A


About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.